Alphabet-backed start-up Isomorphic Labs has added another name to the roster of pharma companies tapping into its AI-based drug discovery engine. Johnson & Johnson's Janssen Biotech unit is the ...

Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.

Google parent Alphabet has drawn on its DeepMind artificial intelligence division to form a drug discovery unit that it calls Isomorphic Labs. The UK-registered company will be able to tap into ...

Jan 20 : Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday. The ...

Jan 20 (Reuters) - Isomorphic Labs, ‌which uses artificial intelligence ‌for drug discovery, expects to have its first clinical trials by the ‍end of 2026, founder and CEO Demis Hassabis said ⁠on ...

Read more: A сentury of сhemical warfare: why the global ban matters Swiss becomes first woman to head chemical weapons body Read more: Swiss becomes first woman to head chemical weapons body Bad ...

Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs. In an interview with Fortune, Isomorphic Labs president Colin ...

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

This proposal is built on top of import attributes and immutable arraybuffer to add the ability to import arbitrary bytes with a common syntax across JavaScript environments. In a similar manner to ...